BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D'souza S, Lau KCK, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol 2020; 26(38): 5759-5783 [PMID: 33132633 DOI: 10.3748/wjg.v26.i38.5759] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Cachay ER, Hadigan C, Mathews WC. Clinical guidelines for screening of liver cirrhosis complications remain, and clinical judgement must prevail. AIDS 2021;35:2211-3. [PMID: 34602589 DOI: 10.1097/QAD.0000000000003022] [Reference Citation Analysis]
2 Leroy H, Han M, Woottum M, Bracq L, Bouchet J, Xie M, Benichou S. Virus-Mediated Cell-Cell Fusion. Int J Mol Sci 2020;21:E9644. [PMID: 33348900 DOI: 10.3390/ijms21249644] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
3 Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
4 Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens 2021;10:1366. [PMID: 34832522 DOI: 10.3390/pathogens10111366] [Reference Citation Analysis]
5 Tang X, Miao Y, Wang J, Cai T, Yang L, Mi D. Identification of Mutator-Derived lncRNA Signatures of Genomic Instability for Promoting the Clinical Outcome in Hepatocellular Carcinoma. Comput Math Methods Med 2021;2021:1205029. [PMID: 34840594 DOI: 10.1155/2021/1205029] [Reference Citation Analysis]
6 Shen E, Zhang J, Lu Y. DEP domain containing 1B (DEPDC1B) exerts the tumor promoter in hepatocellular carcinoma through activating p53 signaling pathway via kinesin family member 23 (KIF23). Bioengineered 2022;13:1103-14. [PMID: 34983303 DOI: 10.1080/21655979.2021.2017629] [Reference Citation Analysis]
7 Diaz-Aragon R, Coard MC, Amirneni S, Faccioli L, Haep N, Malizio MR, Motomura T, Kocas-Kilicarslan ZN, Ostrowska A, Florentino RM, Frau C. Therapeutic Potential of HNF4α in End-stage Liver Disease. Organogenesis 2021;17:126-35. [PMID: 35114889 DOI: 10.1080/15476278.2021.1994273] [Reference Citation Analysis]
8 Dziri S, Rodriguez C, Gerber A, Brichler S, Alloui C, Roulot D, Dény P, Pawlotsky JM, Gordien E, Le Gal F. Variable In Vivo Hepatitis D Virus (HDV) RNA Editing Rates According to the HDV Genotype. Viruses 2021;13:1572. [PMID: 34452437 DOI: 10.3390/v13081572] [Reference Citation Analysis]
9 Elpek GO. Molecular pathways in viral hepatitis-associated liver carcinogenesis: An update. World J Clin Cases 2021; 9(19): 4890-4917 [PMID: 34307543 DOI: 10.12998/wjcc.v9.i19.4890] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Huang X, Glessner JT, Huang J, Zhou D, March ME, Wang H, Xia Q, Hakonarson H, Li J. Discovery of Novel Host Molecular Factors Underlying HBV/HCV Infection. Front Cell Dev Biol 2021;9:690882. [PMID: 34458256 DOI: 10.3389/fcell.2021.690882] [Reference Citation Analysis]
11 Zhao P, Malik S, Xing S. Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC). Front Oncol 2021;11:677926. [PMID: 34336665 DOI: 10.3389/fonc.2021.677926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhang K, Barry AE, Lamm R, Patel K, Schafer M, Dang H. The role of RNA binding proteins in hepatocellular carcinoma. Advanced Drug Delivery Reviews 2022. [DOI: 10.1016/j.addr.2022.114114] [Reference Citation Analysis]
13 Wu BK, Chen QH, Pan D, Chang B, Sang LX. A novel therapeutic strategy for hepatocellular carcinoma: Immunomodulatory mechanisms of selenium and/or selenoproteins on a shift towards anti-cancer. Int Immunopharmacol 2021;96:107790. [PMID: 34162153 DOI: 10.1016/j.intimp.2021.107790] [Reference Citation Analysis]
14 Klöhn M, Schrader JA, Brüggemann Y, Todt D, Steinmann E. Beyond the Usual Suspects: Hepatitis E Virus and Its Implications in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5867. [PMID: 34831021 DOI: 10.3390/cancers13225867] [Reference Citation Analysis]
15 Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World J Gastroenterol 2021; 27(24): 3466-3482 [PMID: 34239263 DOI: 10.3748/wjg.v27.i24.3466] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang Y, Yang Y, Zhao Z, Sun H, Luo D, Huttad L, Zhang B, Han B. A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09465-9] [Reference Citation Analysis]
17 Glitscher M, Hildt E, Bender D. [Hepatitis B and C: mechanisms of virus-induced liver pathogenesis and tumorigenesis]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35015106 DOI: 10.1007/s00103-021-03482-y] [Reference Citation Analysis]
18 Alqahtani SA, Colombo M. Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. Cells 2021;10:3091. [PMID: 34831314 DOI: 10.3390/cells10113091] [Reference Citation Analysis]
19 Wong VC, Wong MI, Lam CT, Lung ML, Lam KO, Lee VH. Hallmark microRNA signature in liquid biopsy identifies hepatocellular carcinoma and differentiates it from liver metastasis. J Cancer 2021;12:4585-94. [PMID: 34149922 DOI: 10.7150/jca.59933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Zhang J, Huang Z, Liu X, Wu C, Zhou W, Ye P, Stalin A, Lu S, Tan Y, Wu Z, Fan X, Zhang X, Wang M, Li B, Cheng G, Mou Y, Wu J, Wan S. Exploring the Multicomponent Synergy Mechanism of Yinzhihuang Granule in Inhibiting Inflammation-Cancer Transformation of Hepar Based on Integrated Bioinformatics and Network Pharmacology. BioMed Research International 2022;2022:1-13. [DOI: 10.1155/2022/6213865] [Reference Citation Analysis]
21 Jiang Y, Han Q, Zhao H, Zhang J. The Mechanisms of HBV-Induced Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:435-50. [PMID: 34046368 DOI: 10.2147/JHC.S307962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Valiakou V, Eliadis P, Karamichali E, Tsitsilonis O, Koskinas J, Georgopoulou U, Foka P. Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment. Int J Mol Sci 2021;22:7961. [PMID: 34360721 DOI: 10.3390/ijms22157961] [Reference Citation Analysis]
23 Sakr MA, Mohamed KAH, Hussein AM, Fouad MH, Allam AS, Safwat E. Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00090-y] [Reference Citation Analysis]
24 Sun T, Zhang J. ETV4 mediates the wnt/β-catenin pathway through transcriptional activation of ANXA2 to promote hepatitis B virus-associated liver hepatocellular carcinoma progression. J Biochem 2021:mvab088. [PMID: 34347084 DOI: 10.1093/jb/mvab088] [Reference Citation Analysis]
25 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2021:gutjnl-2021-324915. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Reference Citation Analysis]
26 Jansons J, Skrastina D, Kurlanda A, Petkov S, Avdoshina D, Kuzmenko Y, Krotova O, Trofimova O, Gordeychuk I, Sominskaya I, Isaguliants M. Reciprocal Inhibition of Immunogenic Performance in Mice of Two Potent DNA Immunogens Targeting HCV-Related Liver Cancer. Microorganisms 2021;9:1073. [PMID: 34067686 DOI: 10.3390/microorganisms9051073] [Reference Citation Analysis]
27 Li YT, Wu HL, Liu CJ. Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. Int J Mol Sci 2021;22:9380. [PMID: 34502289 DOI: 10.3390/ijms22179380] [Reference Citation Analysis]
28 Fung BM, Tabibian JH. Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices. Expert Rev Gastroenterol Hepatol 2021;15:487-96. [PMID: 33682586 DOI: 10.1080/17474124.2021.1900732] [Reference Citation Analysis]
29 Digifico E, Balinzo S, Belgiovine C. The Dark Side of the Force: When the Immune System Is the Fuel of Tumor Onset. Int J Mol Sci 2021;22:1224. [PMID: 33513730 DOI: 10.3390/ijms22031224] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Hsiao YF, Cheng SB, Lai CY, Liu HT, Huang SC, Huang YC. The Prognostic Role of Glutathione and Its Related Antioxidant Enzymes in the Recurrence of Hepatocellular Carcinoma. Nutrients 2021;13:4071. [PMID: 34836325 DOI: 10.3390/nu13114071] [Reference Citation Analysis]
31 Pascut D, Hoang M, Nguyen NNQ, Pratama MY, Tiribelli C. HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development. Cancers (Basel) 2021;13:2485. [PMID: 34069740 DOI: 10.3390/cancers13102485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Gomez-Quiroz LE, Roman S. Influence of genetic and environmental risk factors in the development of hepatocellular carcinoma in Mexico. Ann Hepatol 2021;:100649. [PMID: 34902602 DOI: 10.1016/j.aohep.2021.100649] [Reference Citation Analysis]
33 Chen CC, Guan G, Qi X, Abulaiti A, Zhang T, Liu J, Lu F, Chen X. Pacbio Sequencing of PLC/PRF/5 Cell Line and Clearance of HBV Integration Through CRISPR/Cas-9 System. Front Mol Biosci 2021;8:676957. [PMID: 34485380 DOI: 10.3389/fmolb.2021.676957] [Reference Citation Analysis]
34 Papatheodoridi A, Papatheodoridis G. Hepatocellular carcinoma: the virus or the liver? Liver Int 2022. [PMID: 35319167 DOI: 10.1111/liv.15253] [Reference Citation Analysis]
35 Chen YJ, Shen CJ, Yu SH, Lin CL, Shih HM. Increased risk of hepatocellular carcinoma in patients with traumatic liver injury: Real-world data from a nationwide population-based study. Medicine (Baltimore) 2022;101:e28837. [PMID: 35147128 DOI: 10.1097/MD.0000000000028837] [Reference Citation Analysis]